Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 44

1.

Ex Vivo Profiling of PD-1 Blockade Using Organotypic Tumor Spheroids.

Jenkins RW, Aref AR, Lizotte PH, Ivanova E, Stinson S, Zhou CW, Bowden M, Deng J, Liu H, Miao D, He MX, Walker W, Zhang G, Tian T, Cheng C, Wei Z, Palakurthi S, Bittinger M, Vitzthum H, Kim JW, Merlino A, Quinn M, Venkataramani C, Kaplan JA, Portell A, Gokhale PC, Phillips B, Smart A, Rotem A, Jones RE, Keogh L, Anguiano M, Stapleton L, Jia Z, Barzily-Rokni M, Cañadas I, Thai TC, Hammond MR, Vlahos R, Wang ES, Zhang H, Li S, Hanna GJ, Huang W, Hoang MP, Piris A, Eliane JP, Stemmer-Rachamimov AO, Cameron L, Su MJ, Shah P, Izar B, Thakuria M, LeBoeuf NR, Rabinowits G, Gunda V, Parangi S, Cleary JM, Miller BC, Kitajima S, Thummalapalli R, Miao B, Barbie TU, Sivathanu V, Wong J, Richards WG, Bueno R, Yoon CH, Miret J, Herlyn M, Garraway LA, Van Allen EM, Freeman GJ, Kirschmeier PT, Lorch JH, Ott PA, Hodi FS, Flaherty KT, Kamm RD, Boland GM, Wong KK, Dornan D, Paweletz CP, Barbie DA.

Cancer Discov. 2018 Feb;8(2):196-215. doi: 10.1158/2159-8290.CD-17-0833. Epub 2017 Nov 3.

PMID:
29101162
2.

Social inclusion for children with hearing loss in listening and spoken Language early intervention: an exploratory study.

Constantinescu-Sharpe G, Phillips RL, Davis A, Dornan D, Hogan A.

BMC Pediatr. 2017 Mar 14;17(1):74. doi: 10.1186/s12887-017-0823-y.

3.

Newborn hearing screening in Queensland 2009-2011: Comparison of hearing screening and diagnostic audiological assessment between term and preterm infants.

Calcutt TL, Dornan D, Beswick R, Tudehope DI.

J Paediatr Child Health. 2016 Aug 13. doi: 10.1111/jpc.13281. [Epub ahead of print]

PMID:
27521761
4.

A multicentre clinical evaluation of paediatric cochlear implant users upgrading to the Nucleus(®) 6 system.

Plasmans A, Rushbrooke E, Moran M, Spence C, Theuwis L, Zarowski A, Offeciers E, Atkinson B, McGovern J, Dornan D, Leigh J, Kaicer A, Hollow R, Martelli L, Looi V, Nel E, Del Dot J, Cowan R, Mauger SJ.

Int J Pediatr Otorhinolaryngol. 2016 Apr;83:193-9. doi: 10.1016/j.ijporl.2016.02.004. Epub 2016 Feb 21.

5.

Long-term Communication Outcomes for Children Receiving Cochlear Implants Younger Than 12 Months: A Multicenter Study.

Dettman SJ, Dowell RC, Choo D, Arnott W, Abrahams Y, Davis A, Dornan D, Leigh J, Constantinescu G, Cowan R, Briggs RJ.

Otol Neurotol. 2016 Feb;37(2):e82-95. doi: 10.1097/MAO.0000000000000915.

PMID:
26756160
6.

Gene expression of INPP5F as an independent prognostic marker in fludarabine-based therapy of chronic lymphocytic leukemia.

Palermo G, Maisel D, Barrett M, Smith H, Duchateau-Nguyen G, Nguyen T, Yeh RF, Dufour A, Robak T, Dornan D, Weisser M; REACH investigators.

Blood Cancer J. 2015 Oct 2;5:e353. doi: 10.1038/bcj.2015.82.

7.

Collagen degradation products measured in serum can separate ovarian and breast cancer patients from healthy controls: A preliminary study.

Bager CL, Willumsen N, Leeming DJ, Smith V, Karsdal MA, Dornan D, Bay-Jensen AC.

Cancer Biomark. 2015;15(6):783-8. doi: 10.3233/CBM-150520.

PMID:
26406420
8.

Serum biomarkers reflecting specific tumor tissue remodeling processes are valuable diagnostic tools for lung cancer.

Willumsen N, Bager CL, Leeming DJ, Smith V, Christiansen C, Karsdal MA, Dornan D, Bay-Jensen AC.

Cancer Med. 2014 Oct;3(5):1136-45. doi: 10.1002/cam4.303. Epub 2014 Jul 18.

9.

PTK2 expression and immunochemotherapy outcome in chronic lymphocytic leukemia.

Weisser M, Yeh RF, Duchateau-Nguyen G, Palermo G, Nguyen TQ, Shi X, Stinson SY, Yu N, Dufour A, Robak T, Salogub GN, Dmoszynska A, Solal-Celigny P, Warzocha K, Loscertales J, Catalano J, Larratt L, Rossiev VA, Bence-Bruckler I, Geisler CH, Montillo M, Fischer K, Fink AM, Hallek M, Bloehdorn J, Busch R, Benner A, Döhner H, Valente N, Wenger MK, Stilgenbauer S, Dornan D.

Blood. 2014 Jul 17;124(3):420-5. doi: 10.1182/blood-2013-12-538975. Epub 2014 Jun 10.

10.

A pilot study of telepractice delivery for teaching listening and spoken language to children with hearing loss.

Constantinescu G, Waite M, Dornan D, Rushbrooke E, Brown J, McGovern J, Ryan M, Hill A.

J Telemed Telecare. 2014 Apr;20(3):135-40. doi: 10.1177/1357633X14528443. Epub 2014 Mar 18.

PMID:
24643949
11.

Extracellular matrix specific protein fingerprints measured in serum can separate pancreatic cancer patients from healthy controls.

Willumsen N, Bager CL, Leeming DJ, Smith V, Karsdal MA, Dornan D, Bay-Jensen AC.

BMC Cancer. 2013 Nov 21;13:554. doi: 10.1186/1471-2407-13-554.

12.

Integrated genomic analysis of triple-negative breast cancers reveals novel microRNAs associated with clinical and molecular phenotypes and sheds light on the pathways they control.

de Rinaldis E, Gazinska P, Mera A, Modrusan Z, Fedorowicz GM, Burford B, Gillett C, Marra P, Grigoriadis A, Dornan D, Holmberg L, Pinder S, Tutt A.

BMC Genomics. 2013 Sep 23;14:643. doi: 10.1186/1471-2164-14-643.

13.

miR-221/222 targets adiponectin receptor 1 to promote the epithelial-to-mesenchymal transition in breast cancer.

Hwang MS, Yu N, Stinson SY, Yue P, Newman RJ, Allan BB, Dornan D.

PLoS One. 2013 Jun 11;8(6):e66502. doi: 10.1371/journal.pone.0066502. Print 2013.

14.

DCDT2980S, an anti-CD22-monomethyl auristatin E antibody-drug conjugate, is a potential treatment for non-Hodgkin lymphoma.

Li D, Poon KA, Yu SF, Dere R, Go M, Lau J, Zheng B, Elkins K, Danilenko D, Kozak KR, Chan P, Chuh J, Shi X, Nazzal D, Fuh F, McBride J, Ramakrishnan V, de Tute R, Rawstron A, Jack AS, Deng R, Chu YW, Dornan D, Williams M, Ho W, Ebens A, Prabhu S, Polson AG.

Mol Cancer Ther. 2013 Jul;12(7):1255-65. doi: 10.1158/1535-7163.MCT-12-1173. Epub 2013 Apr 18.

15.

Inactivation of TP53 correlates with disease progression and low miR-34a expression in previously treated chronic lymphocytic leukemia patients.

Dufour A, Palermo G, Zellmeier E, Mellert G, Duchateau-Nguyen G, Schneider S, Benthaus T, Kakadia PM, Spiekermann K, Hiddemann W, Braess J, Truong S, Patten N, Wu L, Lohmann S, Dornan D, GuhaThakurta D, Yeh RF, Salogub G, Solal-Celigny P, Dmoszynska A, Robak T, Montillo M, Catalano J, Geisler CH, Weisser M, Bohlander SK.

Blood. 2013 May 2;121(18):3650-7. doi: 10.1182/blood-2012-10-458695. Epub 2013 Mar 22.

16.

To respond or not to respond to CD40 agonism: That is the prediction.

Shi X, Dornan D.

Oncoimmunology. 2012 Jan 1;1(1):83-85.

17.

Fc gamma receptor 3a genotype predicts overall survival in follicular lymphoma patients treated on SWOG trials with combined monoclonal antibody plus chemotherapy but not chemotherapy alone.

Persky DO, Dornan D, Goldman BH, Braziel RM, Fisher RI, Leblanc M, Maloney DG, Press OW, Miller TP, Rimsza LM.

Haematologica. 2012 Jun;97(6):937-42. doi: 10.3324/haematol.2011.050419. Epub 2012 Jan 22.

18.

Dissecting cancer heterogeneity.

Dornan D, Settleman J.

Nat Biotechnol. 2011 Dec 8;29(12):1095-6. doi: 10.1038/nbt.2063. No abstract available.

PMID:
22158362
19.

miR-221/222 targeting of trichorhinophalangeal 1 (TRPS1) promotes epithelial-to-mesenchymal transition in breast cancer.

Stinson S, Lackner MR, Adai AT, Yu N, Kim HJ, O'Brien C, Spoerke J, Jhunjhunwala S, Boyd Z, Januario T, Newman RJ, Yue P, Bourgon R, Modrusan Z, Stern HM, Warming S, de Sauvage FJ, Amler L, Yeh RF, Dornan D.

Sci Signal. 2011 Aug 9;4(186):pt5. doi: 10.1126/scisignal.2002258.

PMID:
21868360
20.

TRPS1 targeting by miR-221/222 promotes the epithelial-to-mesenchymal transition in breast cancer.

Stinson S, Lackner MR, Adai AT, Yu N, Kim HJ, O'Brien C, Spoerke J, Jhunjhunwala S, Boyd Z, Januario T, Newman RJ, Yue P, Bourgon R, Modrusan Z, Stern HM, Warming S, de Sauvage FJ, Amler L, Yeh RF, Dornan D.

Sci Signal. 2011 Jun 14;4(177):ra41. doi: 10.1126/scisignal.2001538.

21.

CD40 pathway activation status predicts response to CD40 therapy in diffuse large B cell lymphoma.

Burington B, Yue P, Shi X, Advani R, Lau JT, Tan J, Stinson S, Stinson J, Januario T, de Vos S, Ansell S, Forero-Torres A, Fedorowicz G, Yang TT, Elkins K, Du C, Mohan S, Yu N, Modrusan Z, Seshagiri S, Yu SF, Pandita A, Koeppen H, French D, Polson AG, Offringa R, Whiting N, Ebens A, Dornan D.

Sci Transl Med. 2011 Mar 16;3(74):74ra22. doi: 10.1126/scitranslmed.3001620.

22.

Statistical techniques to construct assays for identifying likely responders to a treatment under evaluation from cell line genomic data.

Huang EP, Fridlyand J, Lewin-Koh N, Yue P, Shi X, Dornan D, Burington B.

BMC Cancer. 2010 Oct 27;10:586. doi: 10.1186/1471-2407-10-586.

23.

Cancer: miRNA addiction - depending on life's little things.

Dornan D, Settleman J.

Curr Biol. 2010 Sep 28;20(18):R812-3. doi: 10.1016/j.cub.2010.08.040.

24.

Effect of FCGR2A and FCGR3A variants on CLL outcome.

Dornan D, Spleiss O, Yeh RF, Duchateau-Nguyen G, Dufour A, Zhi J, Robak T, Moiseev SI, Dmoszynska A, Solal-Celigny P, Warzocha K, Loscertales J, Catalano J, Afanasiev BV, Larratt L, Rossiev VA, Bence-Bruckler I, Geisler CH, Montillo M, Wenger MK, Weisser M.

Blood. 2010 Nov 18;116(20):4212-22. doi: 10.1182/blood-2010-03-272765. Epub 2010 Aug 12.

25.

Spinogenesis and pruning in the primary auditory cortex of the macaque monkey (Macaca fascicularis): an intracellular injection study of layer III pyramidal cells.

Elston GN, Okamoto T, Oga T, Dornan D, Fujita I.

Brain Res. 2010 Feb 26;1316:35-42. doi: 10.1016/j.brainres.2009.12.056. Epub 2010 Jan 4.

PMID:
20043887
26.

Deubiquitinase USP9X stabilizes MCL1 and promotes tumour cell survival.

Schwickart M, Huang X, Lill JR, Liu J, Ferrando R, French DM, Maecker H, O'Rourke K, Bazan F, Eastham-Anderson J, Yue P, Dornan D, Huang DC, Dixit VM.

Nature. 2010 Jan 7;463(7277):103-7. doi: 10.1038/nature08646. Epub 2009 Dec 20.

PMID:
20023629
27.

Therapeutic potential of an anti-CD79b antibody-drug conjugate, anti-CD79b-vc-MMAE, for the treatment of non-Hodgkin lymphoma.

Dornan D, Bennett F, Chen Y, Dennis M, Eaton D, Elkins K, French D, Go MA, Jack A, Junutula JR, Koeppen H, Lau J, McBride J, Rawstron A, Shi X, Yu N, Yu SF, Yue P, Zheng B, Ebens A, Polson AG.

Blood. 2009 Sep 24;114(13):2721-9. doi: 10.1182/blood-2009-02-205500. Epub 2009 Jul 24.

28.

Antibody-based targeting of FGFR3 in bladder carcinoma and t(4;14)-positive multiple myeloma in mice.

Qing J, Du X, Chen Y, Chan P, Li H, Wu P, Marsters S, Stawicki S, Tien J, Totpal K, Ross S, Stinson S, Dornan D, French D, Wang QR, Stephan JP, Wu Y, Wiesmann C, Ashkenazi A.

J Clin Invest. 2009 May;119(5):1216-29. doi: 10.1172/JCI38017. Epub 2009 Apr 20.

29.

A case study of the speech, language and vocal skills of a set of monozygous twin girls: one twin with a cochlear implant.

Bell M, Hickson L, Woodyatt G, Dornan D.

Cochlear Implants Int. 2001 Mar;2(1):1-16. doi: 10.1179/cim.2001.2.1.1.

PMID:
18792000
30.

ATM engages autodegradation of the E3 ubiquitin ligase COP1 after DNA damage.

Dornan D, Shimizu H, Mah A, Dudhela T, Eby M, O'rourke K, Seshagiri S, Dixit VM.

Science. 2006 Aug 25;313(5790):1122-6.

31.

Interferon regulatory factor 1 binding to p300 stimulates DNA-dependent acetylation of p53.

Dornan D, Eckert M, Wallace M, Shimizu H, Ramsay E, Hupp TR, Ball KL.

Mol Cell Biol. 2004 Nov;24(22):10083-98.

32.

COP1, the negative regulator of p53, is overexpressed in breast and ovarian adenocarcinomas.

Dornan D, Bheddah S, Newton K, Ince W, Frantz GD, Dowd P, Koeppen H, Dixit VM, French DM.

Cancer Res. 2004 Oct 15;64(20):7226-30.

33.

The ubiquitin ligase COP1 is a critical negative regulator of p53.

Dornan D, Wertz I, Shimizu H, Arnott D, Frantz GD, Dowd P, O'Rourke K, Koeppen H, Dixit VM.

Nature. 2004 May 6;429(6987):86-92. Epub 2004 Apr 21.

PMID:
15103385
34.

Human De-etiolated-1 regulates c-Jun by assembling a CUL4A ubiquitin ligase.

Wertz IE, O'Rourke KM, Zhang Z, Dornan D, Arnott D, Deshaies RJ, Dixit VM.

Science. 2004 Feb 27;303(5662):1371-4. Epub 2004 Jan 22.

35.
36.

DNA-dependent acetylation of p53 by the transcription coactivator p300.

Dornan D, Shimizu H, Perkins ND, Hupp TR.

J Biol Chem. 2003 Apr 11;278(15):13431-41. Epub 2002 Dec 23.

37.

Regulation of the IRF-1 tumour modifier during the response to genotoxic stress involves an ATM-dependent signalling pathway.

Pamment J, Ramsay E, Kelleher M, Dornan D, Ball KL.

Oncogene. 2002 Nov 7;21(51):7776-85.

38.

The conformationally flexible S9-S10 linker region in the core domain of p53 contains a novel MDM2 binding site whose mutation increases ubiquitination of p53 in vivo.

Shimizu H, Burch LR, Smith AJ, Dornan D, Wallace M, Ball KL, Hupp TR.

J Biol Chem. 2002 Aug 9;277(32):28446-58. Epub 2002 Mar 29.

39.
40.

Need to broaden the scope of defining 'health'.

Dornan DH.

Health Aff (Millwood). 1999 Sep-Oct;18(5):269. No abstract available.

PMID:
10495619
41.

Challenges in developing health promotion services for the chronically ill.

Black RB, Dornan DH, Allegrante JP.

Soc Work. 1986 Jul-Aug;31(4):287-93.

PMID:
10277802
42.

New York: HHC kills its own.

Supin R, Dornan D.

Health PAC Bull. 1979 Sep;11(1):19-20. No abstract available.

PMID:
10245900
43.

Literature review. Dental plaque: its inflammatory potential.

Dornan DC.

Periodontal Abstr. 1968 Dec;16(4):38-44. No abstract available.

PMID:
4241912
44.

Acute severe upper gastrointestinal hemorrhage: a review of 195 cases.

GOTT JR Jr, SMITH EL, DORNAN DD.

Ann Intern Med. 1952 Apr;36(4):1001-16. No abstract available.

PMID:
14915377

Supplemental Content

Loading ...
Support Center